INTRODUCTION

The pharmaceutical industry has been among the most innovative while being one of the most highly regulated industries in the United States. Government regulation of pharmaceutical product quality started in 1906 and has evolved into a stringent system of premarket controls over new drug development and introduction. Several recent studies have examined the effects of these regulatory controls on the costs and development periods for new drug entities, the quantity of drug innovation, and delays in new drug therapies available to consumers.

Government laws and regulations indirectly affect the innovation process through the distribution and marketing of pharmaceuticals. In contrast to other products, drugs can be dispensed to an individual only with a physician's prescription. This is true unless the Food and Drug Administration (FDA) has approved the drug for self-medication (i.e., over-the-counter usage). Historically, state antisubstitution laws for prescription drugs have prohibited pharmacists from dispensing a different brand of a drug than the one prescribed by the physicians.

A major structural change taking place in the pharmaceutical industry today is the repeal of state antisubstitution laws. Over forty states have passed product selection or drug substitution laws. While the state-enacted laws have significant differences, essentially all enable pharmacists to substitute generic products (some mandate substitution) unless a physician prevents substitution.

*Professors of Economics, Duke University

1. The Pure Food and Drugs Act was passed in 1906 primarily to deal with food abuses. See W. Wardell & L. Lasagna, Regulation and Drug Development 6 (American Enterprise Institute for Public Policy Research, 1975) [hereinafter cited as W. Wardell & L. Lasagna].


3. See Table 1.
by checking a preprinted box or writing “dispense as written” (DAW) on the prescription form.

Drug substitution laws give rise to a number of interesting medical, economic, and legal questions that are the subject of much discussion and debate. These include the quality and therapeutic equivalence of various manufacturers' products, the anticipated behavior of physicians and pharmacists under the new drug substitution laws, the economic savings to consumers utilizing generic products, and the question of liability in the event of a drug substitution mishap.

This article will focus on the effects of drug substitution laws on innovation incentives. New laws alter the terms of competition between the innovator's brand and imitative drug products. By lowering the barriers to imitative products, substitution laws reduce the expected return on drug innovation.

The effects of drug substitution laws on innovation incentives must be considered in light of government patent or regulatory policies. Since substitution laws alter the expected revenues of a new drug only after the patent expires and alternative suppliers enter the market, their impact on innovational returns depends on the patent protection. The effective patent life for new pharmaceuticals is typically much shorter than the legal life of 17 years due to the long gestation period that is required to develop and gain regulatory approval for a new drug entity. Hence, drug substitution, patent and regulatory policies have potentially significant interactive effects on the incentives for drug innovation investment.

From a normative or policy perspective, these public policies are also obviously interrelated. If changes in drug substitution laws were seen as leading to suboptimal incentives for drug innovation, policymakers have the option of adjusting patent life to increase incentives. It would not be necessary to maintain substitution restrictions on all pharmaceuticals in order to maintain sufficient incentives with respect to drug innovation. This latter objective could be accomplished by changing the patent life on new drugs. This point is developed later in the article. See the Appendix for a theoretical model of the optimal patent life.

In Section II we consider how substitution laws, along with other government policies, affect the private returns to drug innovation. Section III reviews the current status of drug substitution laws and the current evidence concerning their impact on pharmaceutical sales. In Section IV we perform a sensitivity analysis of the effects of substitution laws on the expected returns to innovation using representative data on research and development (R&D) costs, revenues, and other parameters. Section V is a brief summary and conclusion.

II
THE EFFECT OF GOVERNMENT POLICIES ON THE PRIVATE RETURNS TO PHARMACEUTICAL INNOVATION

This Section examines how FDA regulatory policy, patent policy, and drug substitution laws affect the private returns to pharmaceutical innovation activity.

Decisions to develop new drug entities are investment decisions. The decision making environment presumably compares the expected returns from these projects with alternative investment opportunities. Accordingly, we employ a similar conceptual framework to indicate the joint effects of these government policies on innovation decisions. Using this framework we summarize some of the empirical work on the effects of innovation regulation.

A. The R & D Investment Decision

Consider a hypothetical investment project involving the development of a new chemical entity (NCE). Suppose the NCE is expected to be introduced in year t. It will involve R&D and investment costs over m years and earn positive profits for n years after introduction, p of which are subject to patent protection. Then the rate of return, r, for this particular product introduction is found by solving the standard discounted present-value equation:

\[ \sum_{j=0}^{p} \frac{R_{t+j}}{(1+r)^j} + \sum_{j=p+1}^{n} \frac{R_{t+j}}{(1+r)^j} \]

where

- \(C_{t-1}, C_{t-2}, \ldots, C_{t-m}\) are R&D costs and other investment expenditures;
- \(R_t, \ldots, R_{t+p}\) = net income stream before patent expiration;
- \(R_{t+p+1}, \ldots, R_{t+n}\) = net income stream after patent expiration.

This expected rate of return abstracts from potential differences in risk associated with specific development projects. The expected return from each project would have to be adjusted for such risk differentials across projects (unless the firm is risk neutral). The firm’s decision to invest in a particular development project would depend on whether its adjusted rate of return exceeds or falls below the firm’s capital cost, which reflects the opportunity cost of alternative investments for the firm and its shareholders.

B. The Effects of Regulation

Let us consider how FDA regulations influence the factors in this return calculation rate. The most direct effects of regulations are on expected costs. FDA regulations have increased the number of tests and the amount of evi
dence on safety and efficacy that must be accumulated before a drug is marketed. In addition, the regulatory approval process on a new drug application is usually quite lengthy and averages about two years for successful applicants. Regulation tends to increase both development costs (the C_i's) and the gestation time, m, required to produce a new innovation. Both effects increase the present value of costs of an NCE introduction.

In an earlier empirical analysis, we analyzed the effects on R&D costs of the more stringent regulatory environment emanating from the 1962 Kefauver-Harris Amendments. These Amendments expanded FDA controls to include the clinical development process and required firms to provide evidence on drug efficacy as well as safety. Using a comparative international approach, we estimated that increased regulation more than doubled the R&D costs of obtaining NCE during the first decade after the law was passed.

Recently, Ronald Hansen has estimated the value of R&D costs that a firm might expect to have to discover, develop and gain regulatory approval for an NCE introduction. Using detailed cost data on over 100 drug entities tested in human beings, he estimated the present value of R&D costs for a typical NCE introduction to be $54 million (adjusted to reflect 1975 dollar rates). This high value reflects the long gestation period for new drugs and the high attrition rate on unsuccessful R&D projects. Furthermore, Hansen's estimates on R&D costs are at least an order of magnitude greater than estimates available for the immediate pre-1962 amendment period.

It is also appropriate to consider the effects of FDA regulations on the expected revenues from a new NCE. There are a number of possible impacts here, some of which have conflicting implications for expected revenues.

First, regulatory controls will reduce the probability of commercialization for many compounds and lower expected revenues. One of the primary benefits of regulation is the extent that the regulatory agency screens out and deters drug entities that present risks that the majority of consumers would not knowingly and willingly undertake. Evaluating whether the FDA has been too conservative in its risk/benefit decisions is one of the most difficult and controversial areas of regulatory analyses.

Regulation also affects the effective patent life, p, for a new drug entity.

6. Grabowski, Vernon & Thomas, supra note 2.
8. Hansen, supra note 5, at 180.
Since the average time to develop an NCE and gain regulatory approval now far exceeds the time necessary to obtain a patent,¹¹ regulatory-derived increases in development or approval times will operate to lower the effective life of a drug patent. While the length of patent protection has been of secondary import historically in the drug industry, this situation could change dramatically with the repeal of antisubstitution laws. This question will be considered in detail later.

There are also several ways that regulation can operate to increase the expected revenues of drugs approved for marketing by the FDA. First, regulations serve a certification function. Stringent regulatory processes provide physicians and patients with confidence in a new drug's safety and efficacy, thereby facilitating rapid market diffusion and penetration for new drugs. Second, drugs that are approved in a stringent regulatory regime face less actual and potential competition than in an unregulated market. This is true for two basic reasons. First, many marginal drugs will be undeveloped, given the greater costs of developing drugs under regulation. Second, the minimum scale at which R&D can be profitably undertaken will tend to increase under regulation, lowering the number of firms engaged in pharmaceutical innovation. This latter phenomenon was investigated by us and our findings indicate that pharmaceutical innovation has become more concentrated.¹²

How do these effects balance out and what is their net impact on the rate of return to pharmaceutical innovation? While there is no definitive answer to this question, several studies have examined developments in pharmaceutical innovation in the United States and other countries that provide some insights into this question. The facts concerning innovation in the United States indicate, first, that as regulation has become more stringent, R&D costs have risen dramatically, compared to revenues, causing average innovation returns to decline over time.¹³ Second, the annual number of new product introductions has declined significantly.¹⁴ Third, total industry R&D for pharmaceuticals has grown little, if at all, in real terms in recent years. Significantly, drug firms have increased their diversification rate across other industrial fields.¹⁵ A number of factors other than regulation have been advanced in the literature as possible explanations for these developments in pharmaceutical inno-

---

¹¹ See D. Schwartzman, supra note 2, at 163, 166.
¹⁴ For a discussion of these trends and a related discussion on alternative quality adjusted measures of drug innovation, see H. Grabowski, supra note 2, at 17.
¹⁵ See id. at 44. See also J. Virts & J. Weston, supra note 13.
C. The Effects of Drug Substitution Laws

Changes in drug substitution laws affect the income stream of a new drug innovation in the period after patent expiration (i.e., the second term on the right in equation 1). It is clear from this formula that the effect of increased substitution on the returns to drug innovation will depend on: (a) the effective patent life, \( p \); and (b) how net revenues, \( R_j \), are shifted in the postpatent period.

With antisubstitution laws in effect, an innovator's product was able to maintain a favored market position by maintaining the "brand loyalty" of physicians. There are many documented cases where the original product retained a dominant market share at premium prices. How the passage of substitution laws will change this situation remains to be seen. It depends on the behavioral response of physicians, pharmacists, and consumers under these new laws. Initial experiences of various states are discussed in the next Section.

If substitution laws foster increased competition between alternative manufacturers' products, then the degree of patent protection assumes a critical role in the appropriability of drug returns. A shorter effective patent life shifts the impact of drug substitution forward in time, amplifying the impact of revenue losses on the expected return to innovation, \( r \), in equation 1. We present data below to show the effective patent life for pharmaceuticals has been declining and is in the range of nine to twelve years.

The prospect of increased substitution rates after patents expire combined with the relatively short, and declining, effective patent periods could have significant negative implications for innovation returns. This is of course an empirical question.

A principal objective of this article is to perform a sensitivity analysis of the effect of the new state substitution laws on the expected returns to innovation using plausible values for the various parameters in equation 1. To do

16. See Grabowski, Vernon & Thomas, supra note 2, at 137–140 for a discussion of these alternative hypotheses. They include factors such as a depletion of research opportunities, scientific advances in the ability to detect toxicology and increased concerns about product liability.

17. See H. Grabowski, supra note 2, at 24–37 for a survey of relevant work as well as the analysis in our more recent paper: Grabowski, Vernon & Thomas, supra note 2, at 140–43.

18. See the discussion on this point by Brownlee, The Economic Consequences of Regulating Without Regard to Economic Consequences, in Issues in Pharmaceutical Economics 215, 226–27 (R. Chien ed. 1979). See also D. Schwartzman, supra note 2, at 256–58. See also Bureau of Consumer Protection, supra note 4, at 38–54.
this, we will take some representative R&D costs and revenues data and investigate how a range of assumptions on patent lives and the degree of drug substitution influence the expected return to pharmaceutical R&D. In the case of the effective patent life parameter, it is fairly easy to develop a range of plausible values because we can compute the effective patent life for NCE introductions that have come on the market over the past several years. On the other hand, projecting the long run effects of substitution laws on drug industry competition is more difficult. The next Section considers several characteristics of these new laws and available evidence concerning their impact on industry sales revenues in several states.

III

Drug Substitution Laws

A. History and Current Status

U.S. antisubstitution laws were enacted in the early fifties. They were advanced as a response to the drug “counterfeiting” problem, the dispensing by pharmacists of drugs similar in size, color, and packaging to popular brand name products but of unknown quality or origin. Antisubstitution laws were adopted by all fifty states and generally prohibited any form of substitution for the brand denoted on the physician’s prescription. At the time of passage, they had the support of the pharmacists’ and pharmaceutical manufacturers’ major trade associations.19

The impetus for repeal of these laws was development of government cost-containment programs for drugs under state Medicaid plans and growth of the consumer movement in the sixties. In 1970 the American Pharmaceutical Association, a trade association, supported the repeal of antisubstitution laws. A few states, including Florida and California, repealed their laws between 1972 and 1975. The number of states passing substitution laws has accelerated rapidly since 1976.

By the end of 1978, forty states and the District of Columbia had enacted drug substitution laws. Table I provides a list of the major provisions of these laws. As demonstrated in the Table, there is considerable variation in substitution laws from state to state.

All states allow physicians to prevent substitution. In several states, there are two-line prescription forms: one line stating substitution is permitted and the other stating that the prescription must be dispensed as written. In the two-line prescription states, excepting New Jersey, the physician consents to substitution by signing the line permitting substitution. States which do not

---

19. The history and growth of antisubstitution laws is discussed in more detail in Bureau of Consumer Protection, supra note 4, at 141–54.
## Table I

### Major Provisions of State Drug Substitution Laws

<table>
<thead>
<tr>
<th>State</th>
<th>Year Enacted</th>
<th>Formulary Limitations*</th>
<th>Two-Line Rx Form Required</th>
<th>How Substitution Can Be Prevented‡</th>
<th>Pharmacy Substitution Mandatory</th>
<th>Cost Savings Pass-On Required</th>
<th>M.D. Exemption from Liability</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALASKA</td>
<td>1976</td>
<td>None</td>
<td>Yes</td>
<td>C</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>ARIZONA</td>
<td>1978</td>
<td>Positive</td>
<td>Yes</td>
<td>A</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>ARKANSAS</td>
<td>1975</td>
<td>Negative</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>CALIFORNIA</td>
<td>1975</td>
<td>Negative</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>COLORADO</td>
<td>1976</td>
<td>None</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>CONNECTICUT</td>
<td>1976</td>
<td>None</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>DELAWARE</td>
<td>1976</td>
<td>Negative</td>
<td>Yes</td>
<td>A</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>D.C.</td>
<td>1976</td>
<td>Positive</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>FLORIDA</td>
<td>1976</td>
<td>Negative</td>
<td>No</td>
<td>B</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>GEORGIA</td>
<td>1977</td>
<td>None</td>
<td>Yes</td>
<td>A</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>IDAHO</td>
<td>1978</td>
<td>None</td>
<td>Yes</td>
<td>A</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>ILLINOIS</td>
<td>1977</td>
<td>Positive</td>
<td>Yes</td>
<td>A</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>IOWA</td>
<td>1976</td>
<td>Negative</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>KANSAS</td>
<td>1978</td>
<td>None</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>KENTUCKY</td>
<td>1972</td>
<td>Positive</td>
<td>No</td>
<td>B</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>MAINE</td>
<td>1975</td>
<td>None</td>
<td>No</td>
<td>B</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>MARYLAND</td>
<td>1977</td>
<td>Negative</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>MASSACHUSETTS</td>
<td>1976</td>
<td>Positive</td>
<td>Yes</td>
<td>A</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>MICHIGAN</td>
<td>1974</td>
<td>None</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>MINNESOTA</td>
<td>1974</td>
<td>None</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>MISSOURI</td>
<td>1978</td>
<td>Negative</td>
<td>Yes</td>
<td>A</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>MONTANA</td>
<td>1977</td>
<td>None</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>NEBRASKA</td>
<td>1977</td>
<td>Negative</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>NEW HAMPSHIRE</td>
<td>1973</td>
<td>Positive</td>
<td>No</td>
<td>E</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>NEW JERSEY</td>
<td>1977</td>
<td>Negative</td>
<td>Yes</td>
<td>B</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>NEW MEXICO</td>
<td>1976</td>
<td>Fed. MAC List</td>
<td>Yes</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>NEW YORK</td>
<td>1977</td>
<td>Positive</td>
<td>Yes</td>
<td>A</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>State</td>
<td>Year</td>
<td>Community Pharmacy NDA-ANDA</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>------</td>
<td>-----------------------------</td>
<td>-----</td>
<td>-------</td>
<td>-----</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>Ohio</td>
<td>1977</td>
<td>No</td>
<td>B</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Oklahoma</td>
<td>1961</td>
<td>None</td>
<td>D</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Oregon</td>
<td>1975</td>
<td>None</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>1976</td>
<td>Positive</td>
<td>A</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Rhode Island</td>
<td>1976</td>
<td>Positive</td>
<td>A</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>South Carolina</td>
<td>1978</td>
<td>None</td>
<td>A</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>South Dakota</td>
<td>1978</td>
<td>None</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Tennessee</td>
<td>1977</td>
<td>Positive</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Utah</td>
<td>1977</td>
<td>Negative&lt;sup&gt;2&lt;/sup&gt;</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Vermont</td>
<td>1978</td>
<td>Positive</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Virginia</td>
<td>1977</td>
<td>Positive</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Washington</td>
<td>1977</td>
<td>Negative&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>West Virginia</td>
<td>1978</td>
<td>Negative&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Wisconsin</td>
<td>1976</td>
<td>Positive</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup> In cases where the actual manufacturer of the product to be substituted is the same as the manufacturer of the prescribed name brand, physician may not prevent substitution.

<sup>2</sup> Board of Pharmacy is empowered but not required to adopt negative formulary.

* A drug formulary, or listing, may be either positive (listing all substitutable drugs) or negative (listing all nonsubstitutable drugs).

† States having a “yes” in this column require two signature lines on all prescriptions. A signature on one line expressly permits substitution, while a signature on the other would prevent it.

‡ Legend:
   A — Physician must give prior approval by signing the appropriate line in the prescription for substitution to occur.
   B — Pharmacist is authorized to substitute unless M.D. indicates express disapproval, such as by indicating “DAW.”
   C — In Alaska, physician must indicate permission to substitute. No permission implies DAW.
   D — In Oklahoma, authority to substitute is with the prescriber or purchaser.
   E — In New Hampshire, physician must write “or its generic equivalent drug listed in N.H. drug formulary” to permit substitution.

have two-line prescription forms allow physicians to prevent substitution by writing DAW (dispense as written) or a similar notation on the prescription form. In these states, the pharmacist is authorized to substitute if the physician does not take positive action to stop substitution. This type of arrangement has been called physician veto as opposed to physician consent for substitution required in two-line prescription forms.

Nine states (Florida, Kentucky, Massachusetts, New York, New Jersey, Rhode Island, Vermont, West Virginia and Pennsylvania) have provisions that make substitution mandatory. These states require pharmacists to substitute lower-cost drugs that they have in stock except where the physician has stipulated otherwise on the prescription. These mandatory laws are of recent origin and some question exists as to their effectiveness and enforceability. This is a question for future research.

Substitution is regulated by drug formularies (listings) in a majority of the states. A positive formulary provides an approved list of drugs for which substitution is permitted, while a negative formulary denotes drugs for which substitution is prohibited.

Other provisions have been included in the substitution laws in various states. Most states, for instance, require that some or all of the cost savings in dispensing generics be passed on to the consumers, but this provision is not well-defined in many cases. A number of states require that patients approve substitution and Alaska requires that the physician be notified if substitution occurs. Finally, several states specifically exempt physicians from liability in the event of an injury arising from substitution.

One important development is that many states are amending their laws to facilitate or even mandate greater substitution. Four states (Florida, Massachusetts, Kentucky and Rhode Island) have amended their laws to require substitution (unless the physician has designated otherwise on the prescription). New Jersey, New York, and Pennsylvania recently passed their first substitution laws and included mandatory substitution provisions. Thus, there is a trend toward substitution laws which increases the likelihood of substitution by providing for substitution or mandating substitution.

The expected level of substitution in any state will depend on the constraints and incentives regarding substitution. This issue is considered in the next two Sections.

B. Evidence on the Effects of Repealing Antisubstitution Laws

Since most substitution laws have been in effect for only a few years, there is not a great deal of empirical evidence available on the effects of such laws. The full market responses to them in most cases have yet to take place. However, studies of the initial experience in particular states have begun to emerge.
An extensive empirical analysis in Michigan of the first year under substitution laws was performed by a research group at Wayne State University, headed by Theodore Goldberg. A major finding of this study was that substitution in Michigan occurred for only 1.5 percent of the multiple-source prescriptions. This was true despite the fact that physicians prohibited substitution (by designating DAW) on only approximately 6 percent of these prescriptions. In a follow-up study, Goldberg and his associates found that when substitution did occur, the average consumer saving was approximately 20 percent of the price of the drug prescribed by the physician.

Professor Joseph Fink studied Delaware’s substitution law and obtained very different findings. In Delaware, a two-line prescription state, physicians signed the DAW line prohibiting substitutions 62 percent of the time. At the same time, pharmacists in Fink’s sample substituted 56 percent of the time when authorized to do so by physicians and the product was supplied by more than one firm.

Recently an FTC contracted staff report published findings of a survey of over 700 pharmacists in seven states (Arkansas, California, Delaware, Minnesota, Oregon, Pennsylvania, and Wisconsin). This survey found a wide variance across states in the behavior of both physicians and pharmacists consistent with the findings of the Michigan and Delaware studies discussed above.

A striking finding of the FTC survey is the large difference in the behavior of physicians in states where the preprinted two-line substitution format is used compared to states where physicians must write DAW or a similar phrase. The FTC study notes:

The study confirmed findings reported elsewhere that physicians rarely (only 1.4% to 5.1% of the time) find it necessary to prohibit substitution by handwriting such indications as “Medically Necessary” or “Dispense as Written.” When physicians have to sign one of two instructions preprinted on the prescription form, however, they sign on the “Dispense as Written” line nearly half (31% to 51%) of the time.

An American Druggist survey of pharmacists in seventeen states found similar results: physicians in states utilizing the two-line prescription format

---

21. Goldberg, et. al., Evaluation of Economic Effects of Drug Product Selection Legislation 9-10 (October 1977) (unpublished paper presented to the American Public Health Association Meetings, study supported by grant number R01 HS 02132 from the National Center for Health Services Research, HRA, Department of HEW).
23. Id. at 7, quoted in Bureau of Consumer Protection, supra note 4, at 188.
25. Id. at 190.
26. AM. DRUGGIST 13 (October 1978).
barred substitution 58.5 percent compared to 8.04 percent for physicians in states without this format.

The FTC survey also found a high variance in the extent of substitution by pharmacists in these states. The median percentage of substitution by pharmacists (where substitution is authorized by physicians and multiple suppliers of a product are available) ranged from 5.2 percent in Arkansas to 45.5 percent in Wisconsin.\(^27\) With only seven observations in this sample, it is not clear what legal provisions are primarily responsible for this variance in pharmacists' behavior. We are collecting data on a larger cross section of states in order to test some hypotheses in this regard.

In any case, this FTC study suggests that substitution has reached significant levels in some states. In addition, it would be plausible to expect the amount of substitution to increase in future periods. In the short run the degree of substitution will be restrained by concerns of physicians, pharmacists, and patients. These concerns include: quality differences among products, low economic incentives, possible risks to pharmacists, and unreliable information about relative drug prices available to consumers. The long run situation should change with respect to most, if not all, of these concerns.

C. Factors Tending to Increase Drug Substitution

Over Future Periods

1. The FTC Model Law

As noted above, many state legislatures appear predisposed to changing laws to facilitate or increase the level of substitution. In this regard, the FTC has recently proposed a model substitution law that includes provisions designed to encourage substitution. The FTC model law would: (a) allow pharmacists to substitute unless the physician writes DAW on the prescription; (b) only permit substitution in accordance with an FDA developed formulary; (c) require that the substitute product be lower priced than the prescribed brand name product, but not requiring all savings to be passed on to the consumer; (d) have an optional feature limiting pharmacists' liability from substitution; and (e) require that the consumer be informed of the substitution.\(^28\)

Available evidence suggests that adoption of the first provision would help remove the significant level of physician restraints on substitution that exist in many states (i.e., two-line prescription states). Furthermore, the above FTC provisions on drug formularies, partial savings passed on to consumers, and limited liability for pharmacists are designed to increase pharmacists' incentives to substitute compared to the present provisions in many state laws.

---

28. Id. at 9-12.
2. FDA Activity on Drug Equivalence

Another factor that has operated to reduce substitution is uncertainty among pharmacists and patients regarding the technical quality and safety of lower-cost substitute products. This uncertainty has been accentuated recently by considerable publicity about possible bioequivalence problems in drug products. The FDA has been heavily involved in investigation of bioequivalence problems in light of HEW's emerging Maximum Allowable Cost (MAC) program. The FDA has published in the Federal Register a list of over 100 drugs that have potential bioequivalence problems.

The FDA's basic substitution position, however, is that except for relatively few drugs actively under investigation for bioequivalence, any multiple source drug with an approved NDA or an abbreviated NDA is equivalent therapeutically and safe to substitute. Recently, the FDA endorsed the New York formulary for containing only therapeutically equivalent products with no bioequivalence or other quality problems. In this regard, FDA Commissioner Kennedy has stated:

... FDA concurrence in the New York list reflects the Agency's view that there is no consistent difference in quality between drug products sold by large and small firms or between drugs sold under a brand name or "generic" name. We have a single standard for drugs in this country.

[...] States that permit substitution and want some assurance of therapeutic equivalence can use this New York State publication with knowledge that [the] FDA has approved all the products on the list and the manufacturers listed have FDA approval to make them.

Furthermore, the fact that the FDA has given formal endorsement to the drugs in the New York formulary, and implicitly to identical drugs appearing on other states' formularies, should minimize the actual and perceived risks of legal liability for pharmacists. In particular, if a pharmacist were to substitute a chemically equivalent product approved by the FDA that is on the state formulary and this substitution subsequently led to patient harm, it is difficult to see how juries could place liability on the pharmacist instead of the manufacturer or another party.

Finally, the FDA is working to resolve the issues of bioequivalence for drugs on the Federal Register list. Accordingly, the number of drugs in this category is likely to decline in the future.

29. Two drug products containing identical amounts of the identical active drug ingredients in identical dosage forms are "chemically equivalent." "Bioavailability" measures how fast and how much of the drug gets into the body, appears in the blood, or is excreted in the urine. Hence, two chemically equivalent products of approximately equal bioavailability are said to be bioequivalent.
30. See Bureau of Consumer Protection, supra note 4, at 134-40, for a description of the MAC program.
3. **Economic Incentives for Pharmacists to Substitute**

Another reason the literature offers for the low substitution rate is the lack of economic incentives for pharmacists to substitute.\(^\text{33}\) It is sometimes argued that pharmacists obtain larger profit margins on higher priced brand name products and that incentives for price competition are dampened by the information imperfections that exist with respect to retail drugs.

Although these conditions may have prevailed in many segments of the retail drug market historically, recent structural changes are making this market more competitive. In particular, the legal barriers to price advertising which operated to increase information imperfection have been largely removed.\(^\text{34}\) Many discount drugstore chains are promoting drug products on the basis of lower prices. The repeal of antisubstitution laws offers these chains a significant opportunity to expand market shares through promoting and dispensing low-cost generic substitutes.

The trade literature recently reported cases where the chain drugstores (e.g., Walgreens, Giant Rexall, and Peoples) have begun large-scale promotional campaigns stressing the price advantages of generic drugs to consumers.\(^\text{35}\) The advertisements of these chains emphasize that they dispense only quality generic products meeting high manufacturing standards. The Giant Rexall chain in Washington has advertised that they have a quality control laboratory staffed by a Ph.D. in pharmacy and two chemists.

In summary, there are strong economic incentives for the discount drugstore chains to promote generic substitutes. As consumers become aware of the potential savings involved in buying such products, it is reasonable to hypothesize that an increased amount of substitution will voluntarily occur in the marketplace.

D. **Implications for the Sensitivity Analysis**

In this Section we have reviewed the current situation of drug substitution and its actual and potential effects on sales revenues. It is clear from this analysis that substitution laws are in an evolutionary state and their long term impact on drug revenues is uncertain. Nevertheless, significant levels of substitution have been obtained in many states, and there are plausible reasons to expect the degree of substitution to rise. Therefore, it is conceivable that drugs now in the R&D phase will encounter higher rates of substitution when their patents expire than is the case for drugs off patent today. Accordingly, we will utilize a broad range of values for this parameter in the sensitivity analysis which follows.

---

\(^{33}\) *See* Bureau of Consumer Protection, *supra* note 4, at 93.


IV

SUBSTITUTION LAWS AND THE DECISION TO INVEST IN RESEARCH AND DEVELOPMENT

This Section examines the decision to invest in R&D and provides a sensitivity analysis of the effect of repealing antisubstitution laws on the expected profits of R&D.

A. Sensitivity Analysis

In accordance with our previous discussion, the rate of return on R&D is derived by equation 1. in Section II, or

\[ \sum_{i=1}^{m} C_{i-1} (1 + r)^i = \sum_{j=0}^{p} \frac{R_{t+j}}{(1 + r)^j} + \sum_{j=p+1}^{n} \frac{R_{t+j}}{(1 + r)^j} \]

In an analysis of pharmaceutical returns on R&D, David Schwartzman obtained data on the sales revenues for NCE introductions from 1966 to 1972.\(^{36}\) He combined this with corresponding data on lagged industry R&D expenditures to discover and develop new drug entities. He then used these data to compute representative time profiles for the costs (C) and net income values (R) in equation 1. above.

As the starting point to our sensitivity analysis, we will utilize the Schwartzman data on R&D costs and revenues (in his earlier rate of return analysis.) We will investigate how sensitive Schwartzman’s estimated returns are to the structural changes occurring in drug substitution.

As a benchmark for our analysis, we employ Schwartzman’s data profiles with the assumption that the typical NCE product life is twenty years and the gross (after-tax) profit margin is 20 percent. The assumptions underlying this case are Schwartzman’s upper bound estimates on profit margin and product life.\(^{37}\) However, these upper bound estimates yield a relatively modest rate of return of 7.5 percent on R&D. Schwartzman projected lower median values for these parameters on the basis of historical experience in the pharmaceutical industry.\(^{38}\) However, we think his upper bound estimates on product lifetimes and profit margins are likely to be representative of what NCE introductions can reasonably expect to achieve given that significantly fewer drugs are being introduced now.\(^{39}\) We are collecting data for a refined analysis of the returns to recent NCE introductions.

However, the purpose of this analysis is not to predict the effect of substitution on the return to R&D with exact precision, but to gauge the sensitivity

---

36. D. Schwartzman, supra note 2, at 139.
37. Id. at 144.
38. Id.
39. See H. Grabowski, supra note 2, at 39–42 for a discussion on this point as well as other criticisms of Schwartzman’s analysis.
of this return to alternative assumptions concerning the extent of substitution and the longevity of patents. Schwartzman's estimates on R&D costs and revenues are adequate for this purpose.

Table II shows the values of annual costs and net incomes which yield the 7.5 percent return. The key assumptions underlying these values are listed as notes in the Table. In Table II, Schwartzman assumes that the stream of net income is constant over the product life except for an introductory growth period (years 11 and 12) and the final years of sales decline (years 29 and 30). He implicitly assumes that the introduction of competing products after patent expiration does not reduce the net income stream. In other words, given a patent life of 17 years from the date of marketing, in year 27 (see Table) net income has the same value as in year 26. For this analysis, we will reduce net income in the year the patent expires and succeeding years to reflect the impact of substitution on the net income stream of the new drug.

<table>
<thead>
<tr>
<th>Year</th>
<th>R&amp;D Cost</th>
<th>Year</th>
<th>Net Income</th>
<th>Year</th>
<th>Net Income</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>−1.22</td>
<td>11</td>
<td>.64</td>
<td>21</td>
<td>1.91</td>
</tr>
<tr>
<td>2</td>
<td>−1.22</td>
<td>12</td>
<td>1.27</td>
<td>22</td>
<td>1.91</td>
</tr>
<tr>
<td>3</td>
<td>−1.22</td>
<td>13</td>
<td>1.91</td>
<td>23</td>
<td>1.91</td>
</tr>
<tr>
<td>4</td>
<td>−1.22</td>
<td>14</td>
<td>1.91</td>
<td>24</td>
<td>1.91</td>
</tr>
<tr>
<td>5</td>
<td>−1.22</td>
<td>15</td>
<td>1.91</td>
<td>25</td>
<td>1.91</td>
</tr>
<tr>
<td>6</td>
<td>−1.22</td>
<td>16</td>
<td>1.91</td>
<td>26</td>
<td>1.91</td>
</tr>
<tr>
<td>7</td>
<td>−1.22</td>
<td>17</td>
<td>1.91</td>
<td>27</td>
<td>1.91</td>
</tr>
<tr>
<td>8</td>
<td>−1.22</td>
<td>18</td>
<td>1.91</td>
<td>28</td>
<td>1.91</td>
</tr>
<tr>
<td>9</td>
<td>−1.22</td>
<td>19</td>
<td>1.91</td>
<td>29</td>
<td>1.27</td>
</tr>
<tr>
<td>10</td>
<td>−1.22</td>
<td>20</td>
<td>1.91</td>
<td>30</td>
<td>.64</td>
</tr>
</tbody>
</table>

Notes: (1) The R&D period is ten years. Costs are in 1972 dollars and reflect the average costs for all new chemical entities introduced in the 1966-72 periods.

(2) Sales revenues are estimated by the average 1972 sales of new chemical entities introduced in the 1962-68 period. Foreign sales are assumed to be 47 percent of U.S. sales.

(3) A 20 percent after-tax profit margin, including R&D expenditures is assumed. Subtracting 2.6 percentage points from this figure to cover working capital and investment in plant for the project yields 17.4 percent which, when applied to sales, produces the net income figures above.

(4) Commercial life of 20 years is assumed. Sales increase to the peak value in the third year and are assumed to be one-third of the peak in the year of introduction and two-thirds of the peak in the next year. A similar decline is assumed at the end of commercial life.

To perform this sensitivity analysis, we must specify representative values for: (a) the effective patent life of an NCE; and (b) the expected percentage reduction in the net income stream due to substitution after patents expire.

As discussed above, the legal patent life is seventeen years, but this does not measure effective patent life in the pharmaceutical industry. Patent life usually begins while the drug is in the developmental and regulatory approval stage. By the time the drug is cleared for marketing the remaining patent protection period is much less than seventeen years.

Table III shows the effective patent life for annual NCE introductions from 1966 through 1977. These data show that the effective patent life has generally been ten to thirteen years for this period. It has been gradually declining in this period. In the last year of the survey (1977) it was 8.9 years. On the basis of these data we estimate rates of return in our sensitivity analysis for three alternative patent lives: 10 years, 12 years and 17 years.

While we are unable to estimate precisely what impact substitution laws will have on the net income stream; on the basis of our discussion in the last Section it would be reasonable to consider a broad range for this parameter. In Table IV we report the rates of return for three alternative percentage reductions of net income: -10, -30 and -50 percent. It should be noted that this parameter denotes the overall change in after-tax profits due to substitution.

### Table III

**Average Effective Patent Life for New Chemical Entities Introduced into the United States from 1966-1977**

<table>
<thead>
<tr>
<th>Year</th>
<th>Average Effective Patent Life (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1966</td>
<td>13.8</td>
</tr>
<tr>
<td>1967</td>
<td>14.1</td>
</tr>
<tr>
<td>1968</td>
<td>13.1</td>
</tr>
<tr>
<td>1969</td>
<td>11.9</td>
</tr>
<tr>
<td>1970</td>
<td>13.0</td>
</tr>
<tr>
<td>1971</td>
<td>13.9</td>
</tr>
<tr>
<td>1972</td>
<td>13.0</td>
</tr>
<tr>
<td>1973</td>
<td>12.0</td>
</tr>
<tr>
<td>1974</td>
<td>12.4</td>
</tr>
<tr>
<td>1975</td>
<td>10.5</td>
</tr>
<tr>
<td>1976</td>
<td>11.4</td>
</tr>
<tr>
<td>1977</td>
<td>8.9</td>
</tr>
</tbody>
</table>

Note: Effective patent life refers to the length of time from the date of FDA approval until the date of patent expiration.

through losses in market shares or through price reductions by the innovating firm resulting from increased competition from generic substitutes.

As expected, the calculated rates of returns in Table IV are lower for shorter patent lives while the percentage reduction due to substitution is greater. Under the most unfavorable conditions for R&D activity considered here—a 10-year patent life and a 50 percent reduction in net income—the rate of return is reduced to 5.6 percent, or by about 25 percent from the 7.5 percent benchmark. On the other hand, when a 30 percent net income reduction and a 12-year patent life are assumed, the return rate is 6.7 percent, or roughly a 10 percent reduction due to substitution. These estimated effects are not negligible and, other things constant, may be expected to make some R&D projects no longer attractive to pharmaceutical manufacturers.

The results in Table IV underscore the fact that the effects of substitution on R&D returns are highly sensitive to the length of patent protection. If the patent life for drugs actually equalled the legal life of seventeen years, the effects of increased substitution on R&D returns would be quite modest. For example, with a seventeen year life, a 50 percent reduction in net income from substitution causes R&D returns to decrease from 7.5 to 7.1 percent in the present example. On the other hand, as patent lives decrease, the effects of drug substitution are magnified.

### Table IV

**Internal Rates of Return for Alternative Assumptions about the Impact of Substitution and the Effective Patent Life**

<table>
<thead>
<tr>
<th>Percentage Reduction in Net Income upon Patent Expiration</th>
<th>Effective Patent Life</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10 Years</td>
</tr>
<tr>
<td>-10</td>
<td>7.1</td>
</tr>
<tr>
<td></td>
<td>(-5.3)</td>
</tr>
<tr>
<td>-30</td>
<td>6.4</td>
</tr>
<tr>
<td></td>
<td>(-14.7)</td>
</tr>
<tr>
<td>-50</td>
<td>5.6</td>
</tr>
<tr>
<td></td>
<td>(-25.3)</td>
</tr>
</tbody>
</table>

Notes: The standard against which the above rates should be compared is a 7.5 percent return. This is the rate of return for the data given in Table II.

(2) It is assumed that at the end of the patent life substitution will result in the alternative reductions in income given above for the remaining years of the 20-year commercial life.

(3) The percentage reductions were applied to total net income even though foreign income should not be affected by substitution. Hence, the implied domestic percentages are somewhat larger than those above.

(4) The numbers in parentheses are the percentage reductions for each rate of return from the standard 7.5 percent return.
The results in Table IV are preliminary in character. The analysis is based on aggregative data sources and contains the simplifying assumptions discussed above. We plan to refine and expand the analytical framework and data for investigating this question in future work. Nevertheless, results suggest that the effects of substitution laws on innovation incentives are consequential in nature and are highly sensitive to the longevity of patent lives over the ranges considered (i.e., 10 to 17 years).

B. Further Remarks on the Research and Development Investment Decision

The substitution of generic for brand name products already off patent and supplied by multiple sources (about one half of all present prescriptions) shifts cash flow from research intensive firms to nonresearch intensive ones. This reduces the supply of internal funds available to the former firms to undertake R&D investment. While most economists would agree that the rate of return expected for new drugs is the key variable in determining R&D investments, several studies have found internal funds to be a significant determinant of pharmaceutical R&D expenditure. This finding is explained by a number of factors, including the high level of uncertainty that surrounds the development of new pharmaceuticals.

In any event, further research on the relation of pharmaceutical industry R&D expenditures to expected returns and other factors appears warranted. Most of the research on this question was performed on data from the fifties and sixties. Given the major structural changes in this industry since then, there is a clear need to examine this question using recent data and refined statistical techniques. This is another issue that we hope to address in future research.

V

SUMMARY AND IMPLICATIONS FOR PUBLIC POLICY

Our sensitivity analysis suggests that substitution may have nonnegligible effects on the level of R&D investment. The reduced incentive to invest in R&D due to substitution is magnified because the effective patent life in pharmaceuticals has been curtailed by five to seven years as a result of the long development and regulatory approval times for new drugs. This analysis makes it clear that the disincentive effects could be offset almost completely by an increase in the effective patent life to a rate of seventeen years. In essence, the substitution laws could serve to make the patent life a more effective policy instrument because entry by generic substitutes will become more

important upon patent expiration. The relevant policy issue then is whether the current effective life of 10-12 years is too long or too short. Some government agencies and officials feel it is too short. Proposed legislative bills have posed that patent life for drugs begin at the point of FDA approval, restoring patent protection to the full 17 years.41 An Advisory Committee to the President's Domestic Policy Review on Industrial Innovation has recommended this policy change for all products subject to premarket regulatory approval and former HEW Secretary Califano proposed that Congress consider this policy measure.42

In the Appendix we present a theoretical model based on Nordhaus' theory of the optimum patent life,44 which sets forth explicitly what the social benefits and costs of changing patent life are. The benefits of a shorter life are identified as the standard monopoly welfare triangle which becomes available upon patent expiration. Another benefit is the saving in R&D resources. The costs of a shorter life are the foregone benefits of the reduced innovation level. Our results here do not provide sufficient information to pass judgment on this issue. We have established that there is likely to be some reduction in R&D investment and, consequently, in the innovation level. On the other hand, it is unlikely that the full information required to calculate the optimum life will be forthcoming. Meanwhile, decisions on the appropriate patent life must be made. While admittedly a "second best" argument, one point to be considered is whether there is any valid reason that the patent life of pharmaceuticals should be five to seven years less than in most American industries. As discussed above, this is a result of the long development and regulatory approval times that have evolved in the past fifteen years rather than the conscious choice of policymakers.

Selection of a specific patent life implies difficult tradeoffs and would be made under considerable uncertainty. The seventeen year patent life in the United States may or may not be viewed as a reasonable policy for balancing the types of errors this policy choice entails (i.e., too little innovation or too much market power). Nevertheless, there would appear to be little basis for a policy of shorter patent lives for ethical drugs. Given the high risks as well as the potential for significant positive externalities connected with the discovery and development of new drug therapies, one might justify longer patent life for drugs compared with other products. In any case, given the current trend

41. Such a provision was contained, for example, in H.R. 12371 introduced into the Ninety-Fifth Congress by Representative Symms. See Hearings on H.R. 11611 (and all other similar and identical bills) before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, 95th Cong., 2d Sess. 2146 (1978) (statement of Hon. Steven D. Symms, a representative in Congress from the State of Idaho).
42. Advisory Subcommittee on Patent and Information Policy, Department of Commerce Advisory Committee on Industrial Innovation, Draft Report Proposal VIII (December 20, 1978).
of policy developments in the ethical drug industry further attention by academicians and policymakers to the tradeoffs involved here would seem highly desirable.

APPENDIX

In this Appendix we present a simple theoretical model designed to represent the benefits and costs of passing substitution laws. The model is basically a reinterpretation of Nordhaus' theory of optimal patent life.\(^1\)

A major problem arises in applying the Nordhaus model to innovation in the drug industry. His model dealt with cost reducing innovations while innovation in the pharmaceutical industry takes the form of new products. If cost reduction innovation takes place, the demand function for the product is unchanged and consumer surplus can be used to evaluate social benefits. New drugs usually replace older, less effective drugs, provide treatment for previously untreatable diseases, or provide effective treatment with fewer contraindications. These forms of innovation imply shifts in traditional demand functions.

Wu suggests that Lancasterian demand functions can be used to model some new drug innovation classes.\(^2\) Lancaster's theory assumes that satisfaction is derived from the product characteristics rather than from the products themselves.\(^3\) For example, pain relief would be a characteristic and a new drug can be viewed as providing pain therapy units more efficiently than an old drug. In what follows we shall postulate the

---

2. S. Wu, Measures for Social Rates of Return from Pharmaceutical Innovations 7 (1978) (unpublished report on file with the authors of this article).
existence of Lancasterian demand functions. Although we recognize the sometimes strained applicability of this approach to new drug innovation, it does serve to illustrate the benefits and costs of passing substitution laws and the important role of patent life.

We begin with a situation in which substitution is not allowed. Pharmacists must supply the consumer with the brand name drug prescribed by the doctor.

1. Let the demand for pain therapy units be as shown in Figure 1. For simplicity we shall consider only one characteristic here (i.e., pain relief).
2. Prior to innovation, the competitive price-quantity equilibrium is \( P_0, X_0 \).
3. The innovator chooses its profit-maximizing level of R&D inputs which results in a new drug that is more efficient in providing pain relief. This greater efficiency is reflected in its lower unit cost, \( C_0 \). The cost saving \( P_0 C_0 \) is referred to by Nordhaus as the size of the innovation.
4. The size of the innovation, \( P_0 C_0 \), depends positively on the level of R&D inputs. This is Nordhaus' invention possibility function.
5. The innovating firm is assumed to appropriate all the cost saving benefits of the new drug, \( P_0 ABC_0 \). (More realistically, the initial price of the new drug would be set below \( P_0 \) thereby passing on some of the benefits to consumers.)

Hence, the profit-maximizing level of R&D investment prior to passing substitution laws can be represented mathematically as yielding a net present value of:

\[
B_0 = \int_0^\infty [P_0 ABC_0] e^{-rt} dt - R_0
\]

where:
(a) \( P_0 ABC_0 \) is the flow of net revenues to the innovator;
(b) \( r \) is the appropriate discount rate;
(c) \( R_0 \) is the dollar value of R&D investment compounded to time \( t = 0 \).

A key assumption is that the innovator appropriates \( P_0 ABC_0 \) indefinitely over the future. The rationale is that entry after patent expiration is taken to be completely ineffective because of brand loyalties built up over the patent period, and the existence of antisubstitution laws. While this is admittedly unrealistic, it greatly simplifies the analysis and there is some empirical support for strong brand loyalty barriers.

If the firm's discount rate equals society's discount rate, and if \( R_0 \) is equal to total social R&D investment, then \( B_0 \) also represents the present value of society's net benefits. We now show the benefits and costs to society resulting from enactment of substitution laws.

In terms of our simple model, passing substitution laws can be conceived of as a reduction in the period of appropriability by the innovator from the infinite life above to some finite period \( T \), the patent life. We assume that upon patent expiration, substitution will bring about (as a result of entry by generic drug suppliers) a drop in price from \( P_0 \) to \( C_0 \). This permits consumers to share in the benefits by transferring the cost savings \( P_0 ABC_0 \) to them plus enabling them to obtain the welfare triangle ABD, as a result of the expansion in output.

While the above benefits characterization is correct in the short run for existing drugs, the appropriate comparison requires a long run view. The reduction in expected profits to innovating firms should result in a reduced level of R&D investment and a consequent reduction in the typical size of innovation.

In Figure 2 we show the long run comparison between the amount of innovation before and after the passage of substitution laws.
As before the present value of net social benefits before repeal is:

\[
B_0 = \int_0^\infty [P_0ABC_0] e^{-rt} \, dt - R_0.
\]

After repeal, the size of innovation is reduced to \(P_0C_1\). Upon patent expiration in period \(T\), price falls to \(C_1\) and output expands to \(X_1\). We can write the present value of net social benefits as:

\[
B_1 = \int_0^\infty [P_0AEC_1] e^{-rt} \, dt + \int_T^\infty [AFE] e^{-rt} \, dt - R_1.
\]

The change in net benefits is simply the difference between \(B_1\) and \(B_0\). This can be written as:

\[
\Delta B = -\int_0^\infty [C_1EBC_0] e^{-rt} \, dt + \int_T^\infty [AFE] e^{-rt} \, dt + (R_0 - R_1)
\]

or,

\[
\Delta B = -!\frac{C_1EBC_0}{r} + \frac{[AFE] e^{-rt}}{r} + (R_0 - R_1).
\]

The three above terms represent the costs and benefits of passing substitution laws. In particular, the first term is negative and represents the reduced innovation. The two positive terms represent the benefits: one is the gain of the welfare triangle which becomes available only upon patent expiration in period \(T\) and the other is the saving in R&D resources.
Of course, the model sketched above is abstract and is based upon strong assumptions. Nordhaus has discussed these assumptions and the effect of relaxing them elsewhere. We shall not repeat his discussion here.\textsuperscript{4} However, there are several points peculiar to the application of the model here that warrant brief comments.

One interpretation of the comparison above is that the new substitution laws make the patent life an effective policy instrument. If the patent life can be viewed as becoming a policy variable as a result of the passage of substitution laws, then the model suggests that policymakers should not consider the benefits and costs of substitution laws independently of the patent life. In short, if the existing $T$ is such that passage of substitution laws makes $\Delta B$ negative, policymakers can always offset this by an appropriate choice for a new $T$. In fact, Nordhaus' model determines the optimum $T$ which maximizes the net present value of benefits. Only by chance would one expect the optimum $T$ to equal the existing life which is now on the order of ten-to-twelve years in this industry.

We have not distinguished between consumers and producers in evaluating social benefits. While this is justifiable given our concern with economic efficiency, it is also true that the primary political impetus for passing substitution laws derives from the large transfer expected from producers to consumers.

Finally, we have ignored the issue of possible quality differences between the innovator's new product and the generic drugs that are introduced upon patent life expiration. It is a controversial point as to whether the generic drugs are perfect substitutes for the pioneer drug, as we have implicitly assumed here.

\textsuperscript{4} Nordhaus, \textit{supra} note 1, at 428.